The second phase I/II study investigates the safety and efficacy of an intradermally administrated tumor vaccine (MGN1601) that consists of genetically modified allogeneic (Human) tumor cells for the expression of IL-7, GM-CSF, CD80 and CD154 in combination with the TLR-9 agonist dSLIM (double stem loop immunomodulator) in Patients With Advanced Renal Cell Carcinoma (RCC) (ASET Study). This evidence concerns the gene CSF2 and renal cell carcinoma.